Irrimax Corporation is focused on treating and preventing infections, reducing healthcare costs, improving patient outcomes and increasing the safety of healthcare professionals.
Innovation Technologies, Inc., parent company to Irrimax Corporation, holds the rights to US and worldwide patents that provide broad protection for the use of low-concentration CHG (1% or less) technology. The company’s flagship product, Irrisept, is jet lavage containing low concentration Chlorhexidine Gluconate (CHG) 0.05% in sterile water for irrigation.
Irrimax has attracted experts in the fields of product development, clinical research, manufacturing and distribution. Our management team is committed to leading the organization according to high standards of integrity and accountability. Irrimax Corporation is focused on driving innovation and improving patient outcomes.
The Irrimax clinical team is guided by company goals and input from its medical advisory board.